QIAGEN announced on January 7, 2025, its partnership with Genomics England to support the Generation Study, a first-of-its-kind initiative in the UK. This study aims to sequence the genomes of 100,000 newborns in England to screen for over 200 selected conditions, enabling earlier diagnosis and treatment.
QIAGEN will be the sole provider of clinically relevant variant content for genes included in the point-of-care sequencing test, utilizing its Clinical Knowledge Base. This content will support rapid variant interpretation and reporting of sequencing results, which is crucial for identifying babies at risk for rare diseases.
The Generation Study, officially launched in October 2024, screens for treatable conditions affecting approximately 3,000 babies born annually in the UK. QIAGEN's expert-curated knowledge base, built over two decades, ensures unmatched accuracy and consistency in variant interpretation, supporting this national program to improve health outcomes for thousands of families.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.